SRC | ||||
---|---|---|---|---|
File:SRC's first album.jpg | ||||
Studio album by SRC | ||||
Released | November 1968 | |||
Recorded | Terra-Shirma Sound Studios; Detroit, Michigan | |||
Genre | Psychedelic Rock | |||
Length | 35:51 (original release) 42:45 (1993 release) |
|||
Label | Capitol (original release) One Way Records (1993 release) |
|||
Producer | John Rhys | |||
Professional reviews | ||||
|
||||
SRC chronology | ||||
|
SRC was the eponymous debut studio album by SRC, released in November 1968 on Capitol Records. This would be the only album that Robin Dale would play on as he left shortly after this album was released.
All songs by SRC.
The 1993 One Way Records CD added bonus tracks:
! is an album by The Dismemberment Plan. It was released on October 2, 1995, on DeSoto Records. The band's original drummer, Steve Cummings, played on this album but left shortly after its release.
The following people were involved in the making of !:
Albums of recorded music were developed in the early 20th century, first as books of individual 78rpm records, then from 1948 as vinyl LP records played at 33 1⁄3 rpm. Vinyl LPs are still issued, though in the 21st century albums sales have mostly focused on compact disc (CD) and MP3 formats. The audio cassette was a format used in the late 1970s through to the 1990s alongside vinyl.
An album may be recorded in a recording studio (fixed or mobile), in a concert venue, at home, in the field, or a mix of places. Recording may take a few hours to several years to complete, usually in several takes with different parts recorded separately, and then brought or "mixed" together. Recordings that are done in one take without overdubbing are termed "live", even when done in a studio. Studios are built to absorb sound, eliminating reverberation, so as to assist in mixing different takes; other locations, such as concert venues and some "live rooms", allow for reverberation, which creates a "live" sound. The majority of studio recordings contain an abundance of editing, sound effects, voice adjustments, etc. With modern recording technology, musicians can be recorded in separate rooms or at separate times while listening to the other parts using headphones; with each part recorded as a separate track.
+ (the plus sign) is a binary operator that indicates addition, with 43 in ASCII.
+ may also refer to:
Proto-oncogene tyrosine-protein kinase Src, also known as proto-oncogene c-Src or simply c-Src , is a non-receptor tyrosine kinase protein that in humans is encoded by the SRC gene. This protein phosphorylates specific tyrosine residues in other proteins. An elevated level of activity of c-Src tyrosine kinase is suggested to be linked to cancer progression by promoting other signals. c-Src includes an SH2 domain, an SH3 domain, and a tyrosine kinase domain.
c-Src stands for "cellular Src kinase" and should not be confused with "C-terminal Src kinase" (CSK) which is an enzyme which phosphorylates c-Src at its C-terminus and provides negative regulation of Src's enzymatic activity. c-Src is a widely studied member of non-receptor tyrosine kinases which are not associated with a cell-surface receptor.
Src (pronounced "sarc" as it is short for sarcoma) is a proto-oncogene encoding a tyrosine kinase originally discovered by J. Michael Bishop and Harold E. Varmus, for which they were awarded the 1989 Nobel Prize in Physiology or Medicine. It belongs to a family of non-receptor tyrosine kinases called Src family kinases.
The nuclear receptor coactivator 3 also known as NCOA3 is a protein that, in humans, is encoded by the NCOA3 gene. NCOA3 is also frequently called 'amplified in breast 1' (AIB1), steroid receptor coactivator-3 (SRC-3), or thyroid hormone receptor activator molecule 1 (TRAM-1).
NCOA3 is a transcriptional coactivator protein that contains several nuclear receptor interacting domains and an intrinsic histone acetyltransferase activity. NCOA3 is recruited to DNA promotion sites by ligand-activated nuclear receptors. NCOA3, in turn, acylates histones, which makes downstream DNA more accessible to transcription. Hence, NCOA3 assists nuclear receptors in the upregulation of gene expression.
The ratio of PAX2 to AIB-1 protein expression may be predictive of the effectiveness of tamoxifen in breast cancer treatment.
Nuclear receptor coactivator 3 has been shown to interact with: